Shanghai OPM Biosciences Co., Ltd. provides high-performance cell culture media, custom media development, and end-to-end CRDMO and CRO services for biopharmaceutical and biologics companies. Its offerings support clients across the drug R&D lifecycle, from early discovery and cell line development through clinical and commercial manufacturing.
Subscribe to see SHANGHAI OPM BIOSCIENCES CO., LTD.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SHANGHAI OPM BIOSCIENCES CO., LTD. is a biotechnology company headquartered in China. Xcout tracks 2 named people at SHANGHAI OPM BIOSCIENCES CO., LTD., including Yunfen (Fiona) He (President, OPM US).
A few of SHANGHAI OPM BIOSCIENCES CO., LTD.'s closest competitors — see the full list of competitors and alternatives →
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Shanghai OBiO Technology (Group) Corp., Ltd. is a biotechnology contract development and manufacturing organization (CDMO/CRO) focused on gene and cell therapy services, including viral-vector development and manufacturing. It serves pharmaceutical and biotechnology companies, academic institutions, and research organizations developing gene-therapy and related biologics products.
BioMetas is headquartered in Shanghai, China, providing novel drug development services and acting as a research CRO and CDMO.
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
Kincell Bio operates as a cell therapy contract development and manufacturing organization (CDMO) that serves biopharmaceutical clients. The company provides GMP manufacturing, process and analytical development, chemistry, manufacturing, and controls (CMC) strategy, and characterization and release testing to support cell therapy programs from early development through commercial launch.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about SHANGHAI OPM BIOSCIENCES CO., LTD.? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.